<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39356506</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>e2436888</StartPage><MedlinePgn>e2436888</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2436888</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2024.36888</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Probiotic supplementation may improve bowel movements. However, large, properly designed studies are lacking.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To evaluate the potential benefit of Bifidobacterium animalis subsp lactis HN019 on constipation, expressed as complete spontaneous bowel movements (CSBMs).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This randomized triple-blind placebo-controlled clinical trial with 2 weeks of run-in and 8 weeks of intervention was conducted from December 25, 2020, to February 28, 2022, at 5 hospitals in Shanghai, China. Participants included healthy volunteers with functional constipation according to Rome III criteria, 18 to 70 years of age, and a body mass index (calculated as the weight in kilograms divided by the height in meters squared) of less than 30.0. Eligibility after the run-in phase required the randomized participants to have 3 or fewer CSBMs/wk. Data were analyzed from September 29, 2022, to March 23, 2023, and reported as intention to treat.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="UNASSIGNED">Participants were randomized to receive probiotic (B lactis HN019, 7.0 × 109 colony forming units (CFU)/d in maltodextrin at the start of the study and 4.69 × 109 CFU/d at the end of the study or maltodextrin placebo once a day for 8 weeks.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">Primary outcome was change in CSBMs. Secondary outcomes included use of rescue medication, stool consistency, degree of straining for each bowel movement, abdominal pain, and bloating. Further, dietary habits and physical activity were recorded. Fecal samples were analyzed for moisture content, short-chain fatty acids, branched-chain fatty acids, microbiota composition, and calprotectin.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 283 individuals assessed for eligibility, 229 were randomized to either the placebo (n = 117) or the HN019 (n = 112) group. One participant in the placebo group discontinued due to COVID-19 restrictions. The 229 participants (194 [84.7% female) had a median age of 45 (38-52) years, mean (SD) BMI of 22.8 (2.5), and a mean (SD) of 0.77 (1.0) CSBM/wk. There was no difference in the change of weekly CSBMs from baseline to the end of study between the HN019 (least-square mean change, 0.80 [95% CI, 0.54-1.05]) and placebo (least-square mean change, 0.66 [95% CI, 0.41-0.90]) groups.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">Although probiotics have been reported to improve bowel function, this large, well-conducted randomized clinical trial did not confirm such results. Daily consumption of B lactis HN019 at the tested dose of 4.69 × 109 CFU did not outperform placebo to increase CSBMs.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="UNASSIGNED">Chinese Clinical Trial Registry Identifier: ChiCTR2000029215.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Health, International Flavors &amp; Fragrances, Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Carl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Danisco (China) Holding Co, Ltd, International Flavors &amp; Fragrances, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ala-Jaakkola</LastName><ForeName>Reeta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Health, International Flavors &amp; Fragrances, Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forssten</LastName><ForeName>Sofia D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Health, International Flavors &amp; Fragrances, Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saarinen</LastName><ForeName>Markku</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Health, International Flavors &amp; Fragrances, Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hibberd</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Health, Genomics &amp; Microbiome Science, International Flavors &amp; Fragrances, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouwehand</LastName><ForeName>Arthur C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Health, International Flavors &amp; Fragrances, Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibarra</LastName><ForeName>Alvin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Health, International Flavors &amp; Fragrances, Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dingqiang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Merieux NutriSciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordlund</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>4Pharma AB, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yingxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Shanghai Tongji Hospital, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Xizhong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Shanghai Zhongshan Hospital, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Haixia</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Endoscopy Center, Shanghai Tongren Hospital, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Xinjian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Endoscopy Center, Shanghai 6th People's Hospital, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Xiangjun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Gut Microecology and Associated Major Diseases Research, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="Y">Constipation</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069982" MajorTopicYN="Y">Bifidobacterium animalis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003672" MajorTopicYN="N">Defecation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Ouwehand reported holding patent PL2839836T3 for probiotics for use in reducing symptoms of respiratory disease licensed to Dupont Nutrition &amp; Bioscience ApS, patent WO2009048934A2 for probiotics for use in relieving symptoms associated with gastrointestinal disorders licensed to Danisco A/S, patent WO2007132359A2 for composition licensed to Danisco A/S, patent WO0238798A1 for a method for screening probiotic strains of the genus <i>Bifidobacterium</i> licensed to Raisio Oyj and Bioferme Oy, patent WO9730717A1 for preparation and producing adhesion inhibitors licensed to Arla Foods Group, patent AU2013201783A1 for probiotics for use in reducing the incidence and duration of illness licensed to Dupont Nutrition &amp; Bioscience ApS, patent PL2704704T3 for probiotic bacteria for the topical treatment of skin disorders licensed to Dupont Nutrition &amp; Bioscience ApS, patent WO2021015977A1 for oral health care treatment and related compositions licensed to Dupont Nutrition &amp; Bioscience ApS, patent WO2009014421A1 for probiotics for inducing satiety and/or satiation licensed to Campina Nederland Holding BV, patent WO2008122892A2 for probiotics for use in reducing eosinophilia and respiratory allergies licensed to Danisco A/S, patent WO2023057454A1 for consumption of glutamate and formation of γ-aminobutyric acid by <i>Lactiplantibacillus plantarum</i> licensed to Dupont Nutrition &amp; Bioscience ApS, patent PL1981516T3 for use of probiotic microorganisms for the treatment and prevention of obesity and related disorders licensed to Dupont Nutrition &amp; Bioscience ApS, patent WO2024121103A1 for probiotics for treating and/or preventing conditions associated with <i>Helicobacter pylori</i> colonization licensed to International N&amp;H Denmark ApS, patent WO2018050623A1 for bacteria licensed to Dupont Nutrition &amp; Bioscience ApS, patent EP3821718A1 for probiotics for lactose intolerance licensed to Dupont Nutrition &amp; Bioscience ApS, and patent WO2021203083A2 for compositions for metabolic health licensed to Dupont Nutrition &amp; Bioscience ApS. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39356506</ArticleId><ArticleId IdType="pmc">PMC11447574</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2024.36888</ArticleId><ArticleId IdType="pii">2824333</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Camilleri M, Ford AC, Mawe GM, et al. . Chronic constipation. Nat Rev Dis Primers. 2017;3:17095. doi:10.1038/nrdp.2017.95</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.95</ArticleId><ArticleId IdType="pubmed">29239347</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MH, Hou XH. Comittee NaM. Chinese expert consensus on chronic constipation (2019, GuangZhou). Chin J Digestion. 2019;39(9):22.</Citation></Reference><Reference><Citation>Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25(5):599-608. doi:10.1111/j.1365-2036.2006.03238.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2006.03238.x</ArticleId><ArticleId IdType="pubmed">17305761</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris MS, Daniels OT. Core aspects of clinical development and trials in chronic idiopathic constipation. In: Catto-Smith AG, ed. Constipation—Causes, Diagnosis and Treatment. InTech; 2012:147-172.</Citation></Reference><Reference><Citation>Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC. Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: a double-blind, randomized, placebo-controlled, and dose-ranging trial. Gut Microbes. 2018;9(3):236-251. doi:10.1080/19490976.2017.1412908</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2017.1412908</ArticleId><ArticleId IdType="pmc">PMC6219592</ArticleId><ArticleId IdType="pubmed">29227175</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller PA, Gopal PK, Leyer GJ, et al. . Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol. 2011;46(9):1057-1064. doi:10.3109/00365521.2011.584895</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2011.584895</ArticleId><ArticleId IdType="pmc">PMC3171707</ArticleId><ArticleId IdType="pubmed">21663486</ArticleId></ArticleIdList></Reference><Reference><Citation>EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Guidance on the scientific requirements for health claims related to the immune system, the gastrointestinal tract and defence against pathogenic microorganisms. EFSA J. 2016;14:4369. doi:10.2903/j.efsa.2016.4369</Citation><ArticleIdList><ArticleId IdType="doi">10.2903/j.efsa.2016.4369</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Health and Human Services. Guidance for industry: irritable bowel syndrome—Clinical Evaluation of Drugs for Treatment. May 2012. Accessed August 27, 2024. https://www.fda.gov/media/78622/download</Citation></Reference><Reference><Citation>Bengtsson M, Persson J, Sjölund K, Ohlsson B. Further validation of the visual analogue scale for irritable bowel syndrome after use in clinical practice. Gastroenterol Nurs. 2013;36(3):188-198. doi:10.1097/SGA.0b013e3182945881</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SGA.0b013e3182945881</ArticleId><ArticleId IdType="pubmed">23732784</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol. 2005;40(5):540-551. doi:10.1080/00365520510012208</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365520510012208</ArticleId><ArticleId IdType="pubmed">16036506</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidelines for data processing and analysis of the International Physical Activity Questionnaire (IPAQ)–short and long forms. November 2005. Accessed August 27, 2024. https://biobank.ndph.ox.ac.uk/showcase/ukb/docs/ipaq_analysis.pdf</Citation></Reference><Reference><Citation>Miller LE, Ouwehand AC, Ibarra A. Effects of probiotic-containing products on stool frequency and intestinal transit in constipated adults: systematic review and meta-analysis of randomized controlled trials. Ann Gastroenterol. 2017;30(6):629-639. doi:10.20524/aog.2017.0192</Citation><ArticleIdList><ArticleId IdType="doi">10.20524/aog.2017.0192</ArticleId><ArticleId IdType="pmc">PMC5670282</ArticleId><ArticleId IdType="pubmed">29118557</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schoot A, Helander C, Whelan K, Dimidi E. Probiotics and synbiotics in chronic constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2022;41(12):2759-2777. doi:10.1016/j.clnu.2022.10.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2022.10.015</ArticleId><ArticleId IdType="pubmed">36372047</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin F, Zhang J, Shu L, Han W. Association of dietary fiber intake with newly-diagnosed type 2 diabetes mellitus in middle-aged Chinese population. Nutr J. 2021;20(1):81. doi:10.1186/s12937-021-00740-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-021-00740-2</ArticleId><ArticleId IdType="pmc">PMC8477519</ArticleId><ArticleId IdType="pubmed">34579708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensen NB, Bryrup T, Allin KH, Nielsen T, Hansen TH, Pedersen O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med. 2016;8(1):52. doi:10.1186/s13073-016-0300-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-016-0300-5</ArticleId><ArticleId IdType="pmc">PMC4862129</ArticleId><ArticleId IdType="pubmed">27159972</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y, Shi X, Li G, et al. . Effects of dynamic zero COVID-19 policy on anxiety status and lifestyle changes of pregnant women in rural South China: a survey-based analysis by propensity score matching method. Front Public Health. 2023;11:1182619. doi:10.3389/fpubh.2023.1182619</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1182619</ArticleId><ArticleId IdType="pmc">PMC10323362</ArticleId><ArticleId IdType="pubmed">37427259</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>